Theravance Reports Positive Phase III Data For Telavancin In Hospital-Acquired Pneumonia
This article was originally published in The Pink Sheet Daily
Executive Summary
Telavancin in race with J&J/Basilea’s ceftobiprole in pneumonia indication.
You may also be interested in...
Theravance’s Telavancin NDA Could Get FDA Advisory Committee Review
Antibiotics for skin-structure infections could face new FDA hurdles.
Theravance’s Telavancin NDA Could Get FDA Advisory Committee Review
Antibiotics for skin-structure infections could face new FDA hurdles.
Theravance/Astellas Antibiotic Telavancin “Approvable” At FDA
Complete response to agency will not require additional trials, but may include revising label, re-analysis of data, Theravance CEO says.